Table 1 Characteristics of eligible randomized clinical trials included network meta-analysis
From: Chemotherapy regimens for advanced pancreatic cancer: a systematic review and network meta-analysis
Study: Author (year) | Study design: number of patients | Regimens: arm 1 | Regimens: arm 2 | Outcomes | Publication type | Quality (Sign50) |
|---|---|---|---|---|---|---|
Bramhall (2002) | RCT-double blinded | Gemcitabine (1000 mg/m2) | Gemcitabine + Marismastat | OS | Full-text | ++ |
N1 = 119 | PFS | |||||
N2 = 120 | ORR | |||||
Berlin (2002) | RCT-single blinded | Gemcitabine (1000 mg/m2) | Gemcitabine + 5FU | OS | Full-text | + |
N1 = 162 | PFS | |||||
N2 = 160 | ORR | |||||
VanCustem (2004) | RCT- double blinded | Gemcitabine (1000 mg/m2) | Gemcitabine + Tipifarnib | OS | Full-text | ++ |
N1 = 344 | PFS | |||||
N2 = 344 | ORR | |||||
Rocha Lima (2004) | RCT- single blinded | Gemcitabine (1000 mg/m2) | Gemcitabine + Irinotecan | OS | Full-text | + |
N1 = 180 | ORR | |||||
N2 = 180 | ||||||
Louvet (2005) | RCT- single blinded | Gemcitabine (1000 mg/m2) | Gemcitabine + Exatecan | OS | Full-text | + |
N1 = 156 | PFS | |||||
N2 = 157 | ORR | |||||
Reni (2005) | RCT- single blinded | Gemcitabine (1000 mg/m2) | Gemcitabine + Oxaliplatin | OS | Full-text | + |
N1 = 47 | PFS | |||||
N2 = 52 | ORR | |||||
Riess (2005) | RCT- single blinded | Gemcitabin (1000 mg/m2) | Gemcitabine + epirubicin + cisplatin + 5FU | OS | Abstract | + |
N1 = 238 | PFS | |||||
N2 = 235 | ORR | |||||
Herrmann (2007) | RCT- single blinded | Gemcitabine (1000 mg/m2) | Gemcitabine + 5FU + folinic acid | OS | Full-text | + |
N1 = 159 | PFS | |||||
N2 = 160 | ORR | |||||
Oettle (2005) | RCT- single blinded | Gemcitabine (1000 mg/m2) | Gem + Capecitabine | OS | Full-text | + |
N1 = 282 | PFS | |||||
N2 = 283 | ORR |  | ||||
Abou-Alfa (2006) | RCT- single blinded | Gemcitabine (1000 mg/m2) | Gem + Pemetrexed | OS | Full-text | + |
N1 = 175 | ORR | |||||
N2 = 1175 | ||||||
Heinemann (2006) | RCT- single blinded | Gemcitabine (1000 mg/m2) | Gemcitabine + Cisplatin | OS | Full-text | + |
N1 = 97 | PFS | |||||
N2 = 98 | ||||||
ORR | ||||||
Stathopoulos (2006) | RCT- single blinded | Gemcitabine (1000 mg/m2) | Gemcitabine + Irinotecan | OS | Full-text | + |
N1 = 70 | ORR | |||||
N2 = 60 | ||||||
Poplin (2006) | RCT- single blinded | Gemcitabine (1000 mg/m2) | Gemcitabine + Oxaliplatin | OS | Full-text | + |
N1 = 275 | PFS | |||||
N2 = 272 | ORR | |||||
Moore (2007) | 20 RCT- double blinded | Gemcitabine (1000 mg/m2) | Gemcitabine + Erlotinib | OS | Full-text | ++ |
| Â | PFS | |||||
N1 = 285 | ||||||
N2 = 284 | ORR | |||||
Cunningham (2009) | RCT- single blinded | Gemcitabine (1000 mg/m2) | Gem + Capecitabine | OS | Full-text | + |
N1 = 266 | PFS | |||||
N2 = 267 | ORR | |||||
VanCustem (2009) | RCT- Double blinded | Gemcitabine + Erlotinib | Gem + Erlotinib + Bevacizumab | OS | Full-text | ++ |
N1 = 301 | PFS | |||||
N2 = 306 | ORR | |||||
Philip (2010) | RCT- single blinded | Gemcitabine (1000 mg/m2) | Gemcitabine + Cetuximab | OS | Full-text | ++ |
N1 = 371 | PFS | |||||
N2 = 372 | ORR | |||||
Colucci (2010) | RCT- single blinded | Gemcitabine (1000 mg/m2) | Gem + Cisplatin | OS | Full-text | + |
N1 = 199 | PFS | |||||
N2 = 201 | ORR | |||||
Kindler (2011) | RCT-Double blinded | Gemcitabine (1000 mg/m2) | Gem + Axinitib | OS | Full-text | ++ |
N1 = 315 | PFS | |||||
N2 = 180 | ORR | |||||
Conroy (2011) | RCT- single blinded | Gemcitabine (1000Â mg/m2) | FOLFIRINOX | OS | Full-text | + |
N1 = 171 | PFS | |||||
N2 = 171 | ORR | |||||
Goncalves (2012) | RCT- double blinded | Gemcitabine (1000 mg/m2) | Gem + Sorafenib | OS | Full-text | ++ |
N1 = 52 | PFS | |||||
N2 = 52 | ORR | |||||
Heinemann (2012) | RCT-single blinded | Gemcitabine + Erlotinib | Capecitabine + Erlotinib | OS | Full-text | + |
N1 = 143 | PFS | |||||
N2 = 131 | ORR | |||||
Von Hoff (2013) | RCT- single blinded | Gemcitabine (1000 mg/m2) | Gem + NAB-P | OS | Abstract | + |
N1 = 430 | PFS | |||||
N2 = 431 | ORR |